Q2 FY2026 EarningsRLAY Q2 FY26 results were not disclosed in the provided SEC filing, which instead focused on an amendment to its 'at-the-market' (ATM) equity offering program. The company increased its potential stock issuance capacity from $250M to approximately $463M. Consequently, there is no financial data available to compare against consensus estimates of $0.8M in revenue and a GAAP EPS loss of $0.3873. The primary update is a strategic enhancement of liquidity through potential dilutive equity sales.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Relay Therapeutics(RLAY) the Revenue is 350 K (-48.3%), Miss estimate;the EBIT is -90.82 M (-18.19%), Miss estimate;the EPS is -0.41 (+0%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B48.30%
0.00B18.17%
-0.00B66.47%
EBITMiss expectations
-0.09B18.19%
-0.08B1.90%
-0.01B16.29%
EPSMiss expectations
-0.41--
-0.38735.53%
-0.02275.53%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf